CLRB — Cellectar Biosciences Balance Sheet
0.000.00%
Last trade - 00:00
- $76.36m
- $36.33m
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | — | — | — | — | — |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Cash and Equivalents | |||||
Cash and Short Term Investments | 10.6 | 57.2 | 35.7 | 19.9 | 9.56 |
Prepaid Expenses | |||||
Total Other Current Assets | |||||
Total Current Assets | 11.4 | 57.9 | 36.6 | 20.5 | 10.5 |
Gross Property, Plant And Equipment | |||||
Accumulated Depreciation | |||||
Net Property, Plant And Equipment | 0.784 | 0.638 | 0.549 | 0.979 | 1.59 |
Other Long Term Assets | |||||
Total Assets | 12.3 | 58.7 | 37.2 | 21.6 | 12.1 |
Accounts Payable | |||||
Payable / Accrued | |||||
Accrued Expenses | |||||
Notes Payable / Short Term Debt | |||||
Current Portion of Long Term Debt / Capital Leases | |||||
Total Other Current Liabilities | |||||
Total Current Liabilities | 2.77 | 3.56 | 3.99 | 5.53 | 12.9 |
Total Long Term Debt | |||||
Total Debt | |||||
Total Other Liabilities | |||||
Total Liabilities | 3.19 | 3.86 | 4.16 | 6.08 | 13.4 |
Redeemable Preferred Stock | |||||
Common Stock | |||||
Additional Paid In Capital | |||||
Retained Earnings (Accumulated Deficit) | |||||
Total Equity | 9.06 | 54.8 | 33 | 15.5 | -1.36 |
Total Liabilities & Shareholders' Equity | 12.3 | 58.7 | 37.2 | 21.6 | 12.1 |
Total Common Shares Outstanding | |||||
Total Preferred Shares Outstanding |